Recent Quotes (30 days)

You have no recent quotes
chg | %

Welichem Biotech Inc.  

(Public, CVE:WBI)   Watch this stock  
Find more results for WBI
Jun 19 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.10 - 0.75
Open     -
Vol. 0.00
Mkt cap 16.95M
P/E     -
Div/yield     -
EPS -0.13
Shares 59.46M
Beta -3.09
Inst. own     -

Key stats and ratios

Q1 (Feb '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - 217.48%
Return on average equity - 263.43%
CDP Score - -


316-4475 Wayburne Dr
+1-604-4321703 (Phone)
+1-604-4321704 (Fax)

Website links


Welichem Biotech Inc. is a drug discovery and early-stage drug development company. The Company focuses on new therapeutics for autoimmune/inflammatory diseases and cancers. The Company is dedicated to research and development of its anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. All the Company�s drug candidates are derived from the metabolites of bacterial symbionts of soil living nematodes. Using its Symbiochem technology platform, the Company has developed a robust pipeline of compounds that target various diseases, including inflammatory diseases and cancers. WBI-1001 targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. In July 2014, Welichem Biotech Inc announced that LR Resources Co., Ltd acquired shares and holds 94.1% of shares in the Company.